Skip to main content
. Author manuscript; available in PMC: 2022 Feb 15.
Published in final edited form as: Clin Cancer Res. 2021 Jun 29;27(16):4557–4565. doi: 10.1158/1078-0432.CCR-21-0585

Figure 1. Efficacy of neoadjuvant cemiplimab.

Figure 1.

A) Waterfall plot of percentage change from baseline in target lesions per RECIST 1.1 and color-coded for pathologic response in the same subject; *, indicates recurrence after surgery and radiation. B) Representative pretreatment (left) and post-treatment (right) photographs, coronal computed tomography (CT) images, and micrographs of tumor specimens of a patient who achieved a major pathologic response (6-mm foci of residual viable tumor) following neoadjuvant cemiplimab treatment. pCR, pathologic complete response; MPR, major pathologic response; SD/PD, stable or progressive disease.